Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Accountprinceon Sep 11, 2023 3:04pm
235 Views
Post# 35629939

Baxter Redaction and Interest

Baxter Redaction and InterestThe only customer is Baxter.  They have exclusivity for distribution of PMX and the EAA.  They have already started the marketing program so that upon approval from the FDA they can hit the ground running.  The only reason for Spectral to market more broadly is to gain wider interest in Spectral stock with a view to the stock price moving towards it's true value.  Something the BOD and management have not done very well or at all from my observations.

Baxter is the key.  We have no idea what the deal with them is.  If it was just a series of milestone payments the need for redaction - if there ever was a need - has long passed.  It just isn't a valid reason for witholding the information for almost four years now.  Therefore, there must be something else in the deal that is redactionworthy.  And since we're exceeding expectations on 72 enrolled on the way to 90 enrolled that milestone is effectively achieved - only timing to be determined and that will be by the end of 2023.  I wouldn't be surprised to see Baxter - or KidneyCo - take over the trial at that stage through a buyout of Spectral.  I think the time is drawing near and Spectral has no choice but to get to 90 enrolled by the end of this year.  At which time I'm guessing we may see what is under that redaction ink after four years.  And hopefully the payday we've all been waiting for.




<< Previous
Bullboard Posts
Next >>